REGENXBIO stated that the FDA has placed a clinical hold on the company’s experimental gene therapy program for the treatment of rare childhood diseases.
December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an eight-year high. The dramatic ascent follows the announcement of overwhelmingly positive top-line results from its pivotal Phase 3 HOPE-3 study for
REGENXBIO beats Q3 2025 earnings estimates with strong revenue and a narrower loss. Key gene therapy RGX-202 advances, with topline data expected in early 2026.
FDA extends the decision on Regenxbio's RGX-121 for Hunter syndrome to February 2026 following the submission of new long-term data from pivotal trial patients.
The global economy is sailing into Q3 2025 with a blend of cautious optimism and persistent challenges. While a new tariff regime and elevated geopolitical tensions introduce elements of uncertainty, the underlying currents suggest continued, albeit slower, economic expansion, particularly within the United States. Investors are keenly watching the interplay
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps.
